Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

From Endothelium to Lipids, Through microRNAs and PCSK9: A Fascinating Travel Across Atherosclerosis.

D'Ardes D, Santilli F, Guagnano MT, Bucci M, Cipollone F.

High Blood Press Cardiovasc Prev. 2020 Feb;27(1):1-8. doi: 10.1007/s40292-019-00356-y. Epub 2020 Jan 10. Review.

PMID:
31925708
2.

Dyslipidemia induced inflammatory status, platelet activation and endothelial dysfunction in rabbits: Protective role of 10-Dehydrogingerdione.

El-Seweidy MM, Sarhan Amin R, Husseini Atteia H, El-Zeiky RR, Al-Gabri NA.

Biomed Pharmacother. 2019 Feb;110:456-464. doi: 10.1016/j.biopha.2018.11.140. Epub 2018 Dec 5.

3.

Coronary Endothelial Dysfunction Is Associated With Elevated Serum PCSK9 Levels in People With HIV Independent of Low-Density Lipoprotein Cholesterol.

Leucker TM, Weiss RG, Schär M, Bonanno G, Mathews L, Jones SR, Brown TT, Moore R, Afework Y, Gerstenblith G, Hays AG.

J Am Heart Assoc. 2018 Oct 2;7(19):e009996. doi: 10.1161/JAHA.118.009996.

4.

Lipid Lowering Therapy for Atherosclerotic Cardiovascular Disease: It Is Not So Simple.

Vincent J.

Clin Pharmacol Ther. 2018 Aug;104(2):220-224. doi: 10.1002/cpt.1138.

PMID:
30117592
5.

ADCY9 (Adenylate Cyclase Type 9) Inactivation Protects From Atherosclerosis Only in the Absence of CETP (Cholesteryl Ester Transfer Protein).

Rautureau Y, Deschambault V, Higgins MÈ, Rivas D, Mecteau M, Geoffroy P, Miquel G, Uy K, Sanchez R, Lavoie V, Brand G, Nault A, Williams PM, Suarez ML, Merlet N, Lapointe L, Duquette N, Gillis MA, Samami S, Mayer G, Pouliot P, Raignault A, Maafi F, Brodeur MR, Levesque S, Guertin MC, Dubé MP, Thorin É, Rhainds D, Rhéaume É, Tardif JC.

Circulation. 2018 Oct 16;138(16):1677-1692. doi: 10.1161/CIRCULATIONAHA.117.031134.

PMID:
29674325
6.

Improved endothelial function after short-term therapy with evolocumab.

Maulucci G, Cipriani F, Russo D, Casavecchia G, Di Staso C, Di Martino L, Ruggiero A, Di Biase M, Brunetti ND.

J Clin Lipidol. 2018 May - Jun;12(3):669-673. doi: 10.1016/j.jacl.2018.02.004. Epub 2018 Feb 14.

PMID:
29544724
7.

Best Treatment Strategies With Statins to Maximize the Cardiometabolic Benefits.

Cho KI, Sakuma I, Sohn IS, Hayashi T, Shimada K, Koh KK.

Circ J. 2018 Mar 23;82(4):937-943. doi: 10.1253/circj.CJ-17-1445. Epub 2018 Mar 2. Review.

8.

Sex-Specific Mechanisms of Resistance Vessel Endothelial Dysfunction Induced by Cardiometabolic Risk Factors.

Davel AP, Lu Q, Moss ME, Rao S, Anwar IJ, DuPont JJ, Jaffe IZ.

J Am Heart Assoc. 2018 Feb 16;7(4). pii: e007675. doi: 10.1161/JAHA.117.007675.

9.

PCSK9 deficiency reduces atherosclerosis, apolipoprotein B secretion, and endothelial dysfunction.

Sun H, Krauss RM, Chang JT, Teng BB.

J Lipid Res. 2018 Feb;59(2):207-223. doi: 10.1194/jlr.M078360. Epub 2017 Nov 27.

10.

Peripheral vascular atherosclerosis in a novel PCSK9 gain-of-function mutant Ossabaw miniature pig model.

Hedayat AF, Park KH, Kwon TG, Woollard JR, Jiang K, Carlson DF, Lerman A, Lerman LO.

Transl Res. 2018 Feb;192:30-45. doi: 10.1016/j.trsl.2017.10.007. Epub 2017 Nov 3.

11.

Effects of LDL Receptor Modulation on Lymphatic Function.

Milasan A, Dallaire F, Mayer G, Martel C.

Sci Rep. 2016 Jun 9;6:27862. doi: 10.1038/srep27862.

13.

Berberine, a plant alkaloid with lipid- and glucose-lowering properties: From in vitro evidence to clinical studies.

Pirillo A, Catapano AL.

Atherosclerosis. 2015 Dec;243(2):449-61. doi: 10.1016/j.atherosclerosis.2015.09.032. Epub 2015 Sep 30. Review.

PMID:
26520899
14.

Inducing Persistent Flow Disturbances Accelerates Atherogenesis and Promotes Thin Cap Fibroatheroma Development in D374Y-PCSK9 Hypercholesterolemic Minipigs.

Pedrigi RM, Poulsen CB, Mehta VV, Ramsing Holm N, Pareek N, Post AL, Kilic ID, Banya WA, Dall'Ara G, Mattesini A, Bjørklund MM, Andersen NP, Grøndal AK, Petretto E, Foin N, Davies JE, Di Mario C, Fog Bentzon J, Erik Bøtker H, Falk E, Krams R, de Silva R.

Circulation. 2015 Sep 15;132(11):1003-12. doi: 10.1161/CIRCULATIONAHA.115.016270. Epub 2015 Jul 15.

15.

Protective effects of sirtuins in cardiovascular diseases: from bench to bedside.

Winnik S, Auwerx J, Sinclair DA, Matter CM.

Eur Heart J. 2015 Dec 21;36(48):3404-12. doi: 10.1093/eurheartj/ehv290. Epub 2015 Jun 25. Review.

16.

Cholesterol: the good, the bad, and the ugly - therapeutic targets for the treatment of dyslipidemia.

Elshourbagy NA, Meyers HV, Abdel-Meguid SS.

Med Princ Pract. 2014;23(2):99-111. doi: 10.1159/000356856. Epub 2013 Dec 11. Review.

17.

Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.

Urban D, Pöss J, Böhm M, Laufs U.

J Am Coll Cardiol. 2013 Oct 15;62(16):1401-8. doi: 10.1016/j.jacc.2013.07.056. Epub 2013 Aug 21. Review.

18.

Progress in unraveling the genetics of coronary artery disease and myocardial infarction.

Anderson JL, Carlquist JF, Horne BD, Hopkins PN.

Curr Atheroscler Rep. 2007 Sep;9(3):179-86. Review.

PMID:
18241611

Supplemental Content

Loading ...
Support Center